Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedNew operating-status notice and v3.2.0 release; prior v3.1.0 revision removed.SummaryDifference3%

- Check31 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0. This is a version/revision update; no other content changes are indicated.SummaryDifference0.1%

- Check45 days agoChange DetectedVersion bump: v3.0.2 replaces v3.0.1. The 'Back to Top' element was removed.SummaryDifference0.2%

- Check52 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check59 days agoChange DetectedThe web page has updated its facility name and location details, specifically emphasizing the treatment options for Cholangiocarcinoma, including pembrolizumab and peginterferon alfa-2b.SummaryDifference2%

- Check74 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.